A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine.

IF 2.1 4区医学 Q3 ALLERGY

Allergologia et immunopathologia Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i4.1311

Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi

{"title":"A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine.","authors":"Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi","doi":"10.15586/aei.v53i4.1311","DOIUrl":null,"url":null,"abstract":"Introduction: Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.Methods: Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).Results: Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).Conclusion: Dupilumab was effective and safe in our patients with moderate-to-severe AD.","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"149-152"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i4.1311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.

Methods: Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).

Results: Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).

Conclusion: Dupilumab was effective and safe in our patients with moderate-to-severe AD.

查看原文本刊更多论文

巴西特应性皮炎患者既往接受甲氨蝶呤和环孢素的杜匹单抗治疗。

特应性皮炎（AD）是一种慢性炎症性皮肤病，严重影响患者的生活质量。Dupilumab是巴西首个被批准用于治疗中重度AD的生物制剂。我们的目标是在16周的现实环境中评估dupilumab的有效性和安全性。方法：14例患者在第一次dupilumab注射后的第0、4和16周进行评估。在每次访问时，使用EASI（湿疹面积和严重程度指数）、IGA（研究者整体评估）、SCORAD（特应性皮炎评分）、NRS（瘙痒数值评定量表）和DLQI（皮肤病生活质量指数）测量疾病活动性和严重程度、瘙痒强度和对生活质量的影响。结果：观察到的临床改善是显著的，在治疗的前16周，研究样本中使用的所有评分都有变化（p < 0.0001）。结论：Dupilumab对中重度AD患者有效且安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergologia et immunopathologia 医学-过敏

CiteScore

3.70

自引率

0.00%

发文量

131

审稿时长

6-12 weeks

期刊介绍： Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.